Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD10 | O75832 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786258 | 0.93 | CA1 (0.37) | PSMD10CA1CA9CA12CYP24A1 | |
| SCHEMBL2567795 | 0.81 | ALDH1A1 (0.47) | PSMD10CA1CA9CA12ALDH1A1 | |
| SCHEMBL18934371 | 0.81 | ALDH1A1 (0.47) | PSMD10CA1CA9CA12ALDH1A1 | |
| SCHEMBL18926560 | 0.77 | GAA (0.50) | PSMD10CA1CA9CA12ALDH1A1 | |
| SCHEMBL121411 | 0.77 | CA1 (0.40) | PSMD10CA1CA9CA12ALDH1A1 | |
| SCHEMBL8920888 | 0.77 | PSMD10 (0.44) | PSMD10CA1CA9CA12CYP24A1 | |
| SCHEMBL18926554 | 0.76 | CA2 (0.53) | PSMD10CA1CA9CA12ALDH1A1 | |
| SCHEMBL6957776 | 0.76 | TBXAS1 (0.47) | PSMD10ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7364532 | 0.76 | CA12 (0.43) | PSMD10CA1CA9CA12ALDH1A1 | |
| SCHEMBL17023777 | 0.76 | CA1 (0.39) | PSMD10CA1CA9CA12CYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | BEYANG THERAPEUTICS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4556466-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024032584-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 苏州必扬医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | KDR, FLT1, ERBB2 | PSMD10 4159/4885CA1 3348/4885CA9 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.